Eisai’s Eritoran to Enter Clinical Study for COVID-19 on Global Platform

July 2, 2020
Eisai and Los Angeles based non-profit organization Global Coalition for Adaptive Research (GCAR) said on July 1 that they are set to run a multinational clinical study of the TLR4 antagonist eritoran (E5564) for COVID-19, in partnership with the University...read more